Novartis (NVS) News Today

Shares of Novartis AG (NYSE:NVS) have increased following a series of analyst reaffirmations and earnings upgrades. Weiss Ratings reconfirmed its buy rating, while Zacks Research raised most of its quarterly and full-year EPS forecasts. Market commentary also highlighted strong trading volume, a favorable value-stock profile, and sector momentum after a major pharma pricing deal.

• Positive Sentiment: Weiss Ratings reaffirmed its buy (b) rating on Novartis, underscoring continued analyst confidence. Weiss Ratings
• Positive Sentiment: Zacks Research raised its Q3 2027 EPS forecast to $2.41 from $2.35, reflecting stronger profitability expectations.
• Positive Sentiment: Zacks Research increased its Q1 2027 EPS estimate to $2.31 from $2.26, signaling better near-term earnings momentum.
• Positive Sentiment: Zacks Research boosted its Q4 2026 EPS outlook to $2.19 from $2.16, pointing to improved year-end results.
• Positive Sentiment: Zacks Research raised its Q3 2026 EPS projection to $2.25 from $2.21, indicating upside in mid-year performance.
• Positive Sentiment: Zacks Research increased its Q1 2026 EPS estimate to $2.29 from $2.26, suggesting a stronger start to fiscal 2026.
• Positive Sentiment: Zacks Research lifted its FY 2026 EPS forecast to $9.40 from $9.33, raising full-year profitability expectations.
• Positive Sentiment: Zacks Research boosted its FY 2027 EPS estimate to $10.30 from $10.13, indicating robust long-term earnings growth.
• Positive Sentiment: MarketBeat noted a large increase in trading volume for NVS, potentially reflecting renewed investor interest. MarketBeat Volume Alert
• Positive Sentiment: Zacks Style Scores identified Novartis as a strong value stock, emphasizing its attractive valuation metrics. Zacks Value Stock
• Positive Sentiment: Novartis was highlighted among three large drug stocks to watch as the pharma industry rebounds after a major pricing deal, underscoring sector tailwinds. Zacks Pharma Rally
• Neutral Sentiment: MSN posed the question of whether to buy Novartis shares before October 28, reflecting ongoing debate over optimal entry timing. MSN Buy Before Oct 28
• Negative Sentiment: Zacks Research trimmed its Q2 2026 EPS estimate to $2.67 from $2.69, marking a slight downgrade to near-term earnings forecasts.